Insight Guru Inc.

11/16/2026 | Press release | Distributed by Public on 11/16/2026 15:46

What Is Driving Alnylam Stock

For questions about this article or underlying research, email [email protected].

Alnylam Pharmaceuticals (ALNY) stock rose 5.4% on Friday, November 13, 2026, while the S&P 500 fell 0.4%. The company had no earnings report or SEC filing around the move. Health care stocks climbed that day, with the SPDR health care fund, XLV, up 0.5%. So what was going on in the market that Friday, and how does Alnylam's business fit into it?

Alnylam Rose On A Day AI Stocks Slid

Artificial intelligence stocks slid again on November 13 amid turmoil at Nvidia, and the Nasdaq Composite fell 0.9% that session. Health care went the other way.

Alnylam is a health care company that earns its money from medicines. On its October 29 call, management said its TTR franchise, led by AMVUTTRA, brought in $1.15 billion of its roughly $1.3 billion in third-quarter product revenue.

Did Alnylam Move With Other Biotech Stocks?

Mostly not. Its sub-industry, biotechnology, finished flat. The 78 other companies in it worth $2 billion or more posted a median change of minus 0.1%. Of those, 37 rose and 41 fell, with just three climbing 5% or more, as Alnylam did.

Most of its peers rose, but most of them by much less. Four of Alnylam's five peers rose, and Ionis Pharmaceuticals gained 6.4%, more than Alnylam, while Vertex Pharmaceuticals fell 0.7%. With its sub-industry flat, Alnylam moved largely on its own, alongside a few others such as Ionis.

Where Does Alnylam Stock Stand Now?

A rise this large is not rare for Alnylam, which had six in the prior 365 days, the latest on November 11. Even so, the stock has lost 63.5% over the past twelve months, against an 11.7% gain for the S&P 500. Friday's close of $165.04 was near its lowest close of the year, $151.64 on November 10, and well below the high it reached on December 3, 2025, a close of $473.29.

Most of that loss came earlier, but the past month added to it. The stock is down 29.5% since October 15, and it fell 25.1% on October 29 alone, the day of its third-quarter call. On that call, management said it was not yet satisfied with the underlying demand growth, and it expected 2026 TTR product sales at the low end of its $4.2 billion to $4.5 billion range.

At 4.4 times its sales over the past twelve months, Alnylam is priced above the S&P 500's 3.2 times. The company is expected to report its fourth-quarter 2026 results in February 2027, and management plans to give its first 2027 product revenue guidance with those results. That guidance is the figure to watch.

Want A Second Look At What You Own?

Alnylam Pharmaceuticals is one decision in a portfolio. Whether you work with an advisor or manage your money yourself, a second look at the whole portfolio costs nothing. Our partner advisory firm offers a free written review of your holdings, fees and income plan, with no need to switch.

Get A Free Second Opinion

Spot an error or want more like this? Tell us in 10 seconds.

Insight Guru Inc. published this content on November 16, 2026, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on November 16, 2026 at 21:46 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]